Workflow
体检与看病的区别
icon
Search documents
爱康体检报告纷争持续发酵,双方准备随时对簿公堂
3 6 Ke· 2025-08-01 01:18
Core Viewpoint - The recent controversy surrounding a private health examination institution highlights the importance of service quality in the health check industry, serving as a warning for the entire sector [1][15]. Group 1: Incident Overview - A dispute arose from a health report involving a patient, Ms. Zhang, who was diagnosed with kidney cancer after ten years of examinations at Aikang Group [1][2]. - Ms. Zhang claimed that Aikang failed to alert her about significant health risks, while Aikang asserted that their examinations were accurate and that they have initiated legal action against her for defamation [2][3]. Group 2: Examination Findings - The focus of the dispute includes the cancer embryonic antigen (CEA) test results, which remained normal throughout Ms. Zhang's examinations, despite her later cancer diagnosis [2][5]. - Aikang's last report indicated potential issues with her kidneys, suggesting regular follow-ups, but Ms. Zhang reported no follow-up communication from Aikang [2][14]. Group 3: Industry Context - The private health examination market has seen a significant shift, with private institutions capturing approximately 24% of the market share compared to 69% for public hospitals as of 2023 [15]. - The industry faces challenges related to customer service and follow-up care, with many institutions focusing more on sales than on providing comprehensive health management services [16][12]. Group 4: Examination Packages and Services - Aikang offers a variety of health examination packages, with prices ranging from 98 yuan to 23,968 yuan, including options for cancer screenings [7][10]. - Ms. Zhang's examination package was reportedly a basic one provided by her employer, which included 12 cancer screening tests, but she did not opt for any additional services [7][10]. Group 5: Recommendations and Follow-ups - The examination reports often include numerous recommendations for further specialist consultations, yet the follow-up communication from the institutions has been criticized as inadequate [12][13]. - Aikang's management emphasized the distinction between health examinations and clinical diagnoses, asserting that their role is to identify potential health issues rather than provide definitive medical assessments [13][14].
爱康国宾“漏诊”成罗生门
Bei Jing Shang Bao· 2025-07-30 16:40
Core Viewpoint - Aikang Group held a media briefing on July 30 to address the controversy surrounding Ms. Zhang's ten-year health check-up, denying allegations of misdiagnosis and announcing a formal lawsuit against her for defamation [1][8]. Group 1: Company Response - Aikang Group refuted claims of flaws in Ms. Zhang's kidney examinations and denied any misdiagnosis or missed diagnosis allegations [1]. - The company has filed a lawsuit against Ms. Zhang, which has been accepted by the court [1][8]. - Aikang Group's Vice President, Wang Chaohui, emphasized that early diagnosis of kidney cancer relies more on imaging techniques (CT/MRI) rather than blood tests, clarifying that carcinoembryonic antigen (CEA) is not relevant for kidney cancer screening [3][4]. Group 2: Medical Procedures and Standards - Aikang Group explained that blood samples for serum tests are typically preserved for 1-7 days, making it impossible to provide ten years' worth of blood samples as requested by Ms. Zhang [4]. - The company has submitted all relevant data, including ten years of test reports and quality control results, to the regulatory authorities [4]. - All medical personnel are certified, and the equipment used complies with national regulations, ensuring that the testing process adheres to strict quality control standards [4][7]. Group 3: Clarification on Health Check-ups - Aikang Group's CEO, Zhang Ligang, stated that health check-ups are not equivalent to medical diagnoses, highlighting the differences in service models [6][7]. - The purpose of health check-ups is to identify potential health risks, while definitive diagnoses and treatments are conducted by specialized doctors [6][7]. - The public often misunderstands the boundaries between health check-ups and medical consultations, which can lead to unrealistic expectations regarding the capabilities of routine check-ups [6][7]. Group 4: Ms. Zhang's Claims - Ms. Zhang alleged that her ten-year health check-ups at Aikang Group did not detect any cancer risks, despite her reports indicating abnormalities in 2023 [8][9]. - She was diagnosed with kidney cancer in 2024, which had already progressed to a late stage by the time of detection [5][9]. - Ms. Zhang believes that the alleged misdiagnosis and oversight by Aikang Group contributed to the delay in her treatment [9].